News and Trends 20 Jul 2022 WuXi Biologics to build new center in Singapore as part of $1.4B investment WuXi Biologics, a global contract research, development and manufacturing organization (CRDMO), has announced a 10-year $1.4 billion investment plan. The plan aims to expand the company’s research, development, and large-scale drug substance and drug product (DS/DP) manufacturing capacity and capabilities in Singapore. The company will build a new site that will add 120,000L biomanufacturing capacity […] July 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 Good news for Destiny Pharma’s nasal gel to combat life-threatening infections Clinical stage biotech company, Destiny Pharma, announced today (July 19) a positive update from the U.S. Food and Drug Administration (FDA) on its XF-73 nasal gel phase 3 development plans. The FDA has clarified the phase 3 and U.S. registration pathway for the gel for the prevention of post-surgical staphylococcal infections, and this feedback enables […] July 19, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 Alpenglow Biosciences and CorePlus partner to bring 3D spatial biology to clinical R&D Spatial biology company Alpenglow Biosciences is partnering with CorePlus, a high complexity CLIA-certified clinical and anatomic pathology laboratory, to digitize and analyze tissues in 3D to deliver novel spatial biology insights and accelerate drug development. As part of the partnership, CorePlus will invest in Alpenglow and receive access to Alpenglow’s 3Deep Imager, a hybrid open […] July 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 eureKARE launches synthetic biology studio network eureKARE, a company focused on financing and building next generation biotech companies in the fields of synthetic biology, has launched its first synthetic biology studio in Belgium. In conjunction with this, eureKARE has appointed Georges Rawadi as chief of biotech studio development. eureKARE said its thematic synthetic biology studio model is a novel, flexible approach […] July 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 Cells for Cells treats first patient with exosome-produced therapy for osteoarthritis Cells for Cells (C4C), a clinical-stage biotech allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic diseases, has announced a six-month follow-up of the clinical data from the first patient dosed with an exosome-produced therapy for osteoarthritis. The results were made public at an extracellular vesicles signature series during the ISCT annual meeting in San […] July 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 CN Bio opens new lab to meet increasing market demand for organ-on-chip research services New laboratory facilities have been opened today (July 19) at UK organ-on-chip company CN Bio to meet market demand. The Cambridge-based company’s laboratory space has doubled in response to an increasing need for services as the technology gains traction within drug discovery and development programs. Microphysiological systems CN Bio concentrates on designing single and multi-organ […] July 19, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 Spider silk to be produced for Kraig Biocroft Laboratories after agreement signed Hundreds of kilograms of spider silk will be produced per month after Kraig Biocraft Laboratories joined forces with a contractor. Kraig Labs is a biotechnology company and wants to focus on the development and commercialization of spider silk and expects to achieve its target production levels as early as the first quarter of next year […] July 19, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 19 Jul 2022 The biggest Asia-Pacific biotech investments in June 2022 The lab automation player MegaRobo stole the show in the Asia-Pacific region in June with a mega Series C round of $300 million. Oncology firms Doma Biopharmaceutical and Tessa Therapeutics also led the private biotech investment rankings. The Chinese lab automation developer MegaRobo was the decisive winner of June’s biotech investments in the Asia-Pacific region. […] July 19, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 SINOVAC starts influenza vaccine trial in Chile Sinovac Biotech Ltd., a provider of biopharmaceutical products in China, has initiated a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine in Chile through a collaboration with the Pontificia Universidad Católica de Chile. SINOVAC said the results aim to provide scientific evidence to support its influenza vaccine immunogenicity and protection capacity. This clinical […] July 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 19 Jul 2022 Bayer Consumer Health launches microbiome research call to find new academic partners Campaign launch date: Monday, July 18, 2022. Bayer Consumer Health has launched a call through IN-PART’s Discover platform to find and partner with academic experts and research groups working on microbiome-targeting solutions for upper respiratory illnesses, nutrition and digestive health as well as topical delivery through the skin. The campaign aims to accelerate Bayer’s “Partnering […] July 19, 2022 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 SK Bioscience signs deal with Novavax to manufacture COVID-19 vaccine South Korean company SK Bioscience has extended its partnership with Novavax, Inc., a U.S. biotechnology company specializing in next-generation vaccines, for the manufacturing and supply of Novavax COVID-19 vaccine targeting Omicron variants in prefilled syringes. SK Bioscience and Novavax signed an agreement for the technology transfer of Novavax proprietary COVID-19 variant antigen materials and manufacturing […] July 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 FORTY51 Ventures closes $43M biotech fund and announces first investment FORTY51 Ventures has announced the closing of FORTY51 Ventures I, raising $43 million in its first close. FORTY51’s core strategy focuses on company formation and early-stage investments in biotech with geographic emphasis on Switzerland, France and Germany. FORTY51 Ventures will lead or co-lead early rounds (seed and series A) of its growing portfolio, which will […] July 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email